Clinical trials: Septicemia
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic…
- Trial name
- SYMON II (NCT06654895)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- Bluejay Diagnostics, Inc.
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
VENUS: Septic Gene Expression Using SeptiCyte
The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their…
- Trial name
- VENUS (NCT02127502)
- Where
- 6 sites in United States
- Volunteers
- 379 people
- Sponsor
- Immunexpress
SIRS, Sepsis
Utility of Presepsin in Distinguishing Between Sepsis and SIRS
This is an observational study to evaluate the diagnostic accuracy of presepsin levels to discriminate between sepsis and SIRS upon presentation with critical illness compatible with either sepsis or systemic inflammatory…
- Trial name
- NCT02052895
- Where
- 2 sites in United States
- Volunteers
- 226 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Sepsis
SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis
This Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Intravenous Injection of SY-005（recombinant human annexin…
- Trial name
- NCT04898322
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Bacteremia Sepsis
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K.
- Trial name
- PHENOTECH-1 (NCT05613322)
- Testing
- Resistell Phenotech
- Where
- 3 sites in Austria, Spain and 1 more
- Volunteers
- 246 people
- Sponsor
- Resistell AG
Sepsis, Adult Disease
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Emergency Department, Severe Sepsis
- Trial name
- NCT04804306
- Testing
- Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Beckman Coulter, Inc.
Acute Kidney Injury Due to Sepsis
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting…
- Trial name
- CLEAR-AKI (NCT05996835)
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Novartis Pharmaceuticals
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Sepsis, Septic Shock
ARTICE® Real Data Collection & Observational Trial, Phase 4 Study
The objectives of this registry study are to: 1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3.
- Conditions
- Sepsis, Septic Shock, Immunoparalysis in Septic Shock
- Trial name
- ARTistry (NCT07388628)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Artcline GmbH
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Infectious Disease, Fever
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
The study is an observational blinded Validation study in pediatric patients below 3 years old with a diagnosis of Fever Without Source (FWS).
- Conditions
- Infectious Disease, Fever, Viremia
- Trial name
- NCT03224026
- Where
- Switzerland
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
MRSA Bacteremia
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.
- Trial name
- NCT05225558
- Testing
- Delpazolid, Vancomycin
- Where
- 6 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- LigaChem Biosciences, Inc.
Staphylococcal Infections, Bacteremia
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
The purpose of this study is to establish the tolerability of treatment with human lactoferrin 1-11 peptide (hLF1-11) administered intravenously as a single dose given for 10 consecutive days, to patients with bacteremia due to…
- Trial name
- LIST (NCT00509847)
- Testing
- human lactoferrin peptide 1-11
- Where
- Netherlands
- Sponsor
- AM-Pharma
Severe Sepsis, Acute Heart Failure
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
The purpose of this study is to evaluate the impact that the Venus 1000 non-invasive CVP system has on the management of emergency department (ED) patients with fluid sensitive conditions.
- Trial name
- NCT02258984
- Testing
- Mespere Venus 1000 Non-Invasive CVP System
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mespere Lifesciences Inc.
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
Effect of Lactiplantibacillus Plantarum DAD-13 on Inflammatory Markers in ICU Sepsis Patients
This study investigated whether giving the probiotic Lactiplantibacillus plantarum DAD-13 to sepsis patients in the intensive care unit (ICU) could help reduce inflammation and improve bowel function.
- Conditions
- Sepsis, Systemic Inflammatory Response Syndrome (SIRS), Critical Illness
- Trial name
- LactoSepsis (NCT07072871)
- Testing
- Lactiplantibacillus plantarum DAD-13
- Where
- Indonesia
- Volunteers
- 32 people
- Sponsor
- PT Royal Medikalink Pharmalab
Severe Sepsis, Cardiac Arrest
Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes
A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation.
- Conditions
- Severe Sepsis, Cardiac Arrest, Respiratory Failure
- Trial name
- NCT01692847
- Where
- United Kingdom
- Volunteers
- 678 people
- Sponsor
- Philips Healthcare
Sepsis
Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product
This study is a multi-center, randomized clinical validation. Subjects should be fully informed of this protocol and related risks, and can only be enrolled into this study after signing the informed consent form.
- Trial name
- NCT06426121
- Testing
- test Aerobic/F Culture Vials, control Aerobic/F Culture Vials
- Where
- China
- Volunteers
- 394 people
- Sponsor
- Becton, Dickinson and Company
Non-Small Cell Lung Cancer
Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK
This is a multi-center retrospective observational research study collecting data for participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) up to 6 years before start of data…
- Trial name
- NCT02658747
- Testing
- No intervention
- Where
- 7 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche